The Conversation (0)
Brabant Pharma reported additional long-term data from a continuing prospective study of 12 children and adults with Dravet Syndrome, who were treated with low-dose fenfluramine for an average of 13 years 4 months.
Brabant Pharma reported additional long-term data from a continuing prospective study of 12 children and adults with Dravet Syndrome, who were treated with low-dose fenfluramine for an average of 13 years 4 months.
As quoted in the press release:
The results show that during the period 2011 to 2012, 92% of the patients taking low-dose fenfluramine were either seizure-free or had greatly reduced seizure frequency. Two non-responders dropped out of the 19-year observational study and were replaced by two new patients.
Brabant Pharma Chairman and CEO, Rick Stewart, said:
Low-dose fenfluramine for the treatment of Dravet Syndrome has shown great success in making patients seizure-free or substantially reducing the number of seizures experienced. Making these children seizure-free for an average of six years is immensely impressive and we are continuing to successfully treat patients who have been on the drug for over twenty-one years. The average treatment duration is now over thirteen years. Dravet Syndrome is a rare and catastrophic form of epilepsy with very limited treatment options but with life-threatening consequences for patients. We are very encouraged by these data and expect to advance our clinical strategy with Phase III trials in 2014.
Click here to read the Brabant Pharma press release
